Actual status of therapeutic vaccination in non-small cell lung cancer

Wspolczesna Onkologia

Volumn 18, Issue 2, 2014, Pages 77-84

  Szyszka Barth, Katarzyna ^a   Ramlau, Katarzyna ^b   Goździk Spychalska, Joanna ^b   Spychalski, Łukasz ^a   Bryl, Maciej ^a   Gołda Gocka, Iwona ^a   Kopczyńska, Anna ^b   Barinow Wojewódzki, Aleksander ^a   Ramlau, Rodryg ^a,b  

^a Wielkopolska Center of Pulmonology and Thoracosurgery of Eugenia and Janusz Zeyland   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Immunotherapy; Non small cell lung cancer; Vaccines

Indexed keywords

1E 10; AS 02B; BELAGENPUMATUCEL L; CANCER VACCINE; CIMAVAX; CISPLATIN; COLEY VACCINE; CYCLOPHOSPHAMIDE; EGF VACCINE; MAGE A 3VACCINE; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 3 VACCINE; MUCIN 1; NAVELBINE; PLATINUM; RACOTUMOMAB; TECEMOTIDE; TG 4010; UNCLASSIFIED DRUG; VAXIRA; VIRUS VECTOR;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; DRUG TARGETING; HISTORY OF MEDICINE; HUMAN; IMMUNOREGULATION; LUNG NON SMALL CELL CANCER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR CELL; TUMOR IMMUNITY;

EID: 84902476311     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.42724     Document Type: Review

References (57)

1. Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol 2008; 3 (6 Suppl 2): S164-70.
2. Coley WB. The treatment of malignant tumors by repeated inoculations of erisipelas. With a report of ten original cases. Clin Orthop Relat Res 1991; (262): 3-11.
3. Coley WB. Late results of the treatment of inoperable sarcoma by mixed toxins of erysipelas and bacillus prodigiosus. Am J Med Sci 1906; 131: 375-430.
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumor. Proc Natl Acad Sci U S A 1975; 72: 3666-70.
5. Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin infection on transplanted tumors in the mouse. Nature 1959; 184 (Suppl 5): 291-2.
6. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin- 2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-92.
7. Murala S, Alli V, Kreisel D, Gelman AE, Krupnick AS. Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis 2010; 2: 237-44.
8. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience. Lung Cancer 2011; 73: 11-7.
9. Upadhyaya SK. Immunotherapy for cancer with special reference to lung cancer. Apollo Medicine 2006; 3: 277-84.
10. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71: 907-20.
11. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16: 3-15.
12. Widen K, Mozaffari F, Choudhury A, Melstedt H. Overcoming immunosuppressive mechanisms. Ann Oncol 2008; 19: 241-7.
13. Korst RJ, Crystal RG. Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification. Ann Thorac Surg 2003; 76: 1319-26.
14. Toes R, Offringa R, Blom R, Melief CJ, Kast WM. Peptide vaccination can lead to enhance tumor growth through specific T cell tolerance induction. Proc Natl Acad Sci U S A 1996; 93: 7855-60.
15. Akhurst RJ, Derynck R. TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 2001; 11: S44-51.
16. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001; 24: 392-407.
17. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996; 73: 148-153.
18. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158: 4521-4.
19. Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire. M Melanoma-associated antigen (MAGE-A3) expression in stages I and II non-small cell lung cancer; results of a multi-center study. Eur J Cardiothorac Surg 2004; 25: 131-4.
20. Brichard VG, Ejeune D. GK's antigen-specyfic cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine 2007; 25: B61-71.
21. Grah J, Samija M, Juretić A, Sarcević B, Sobat H. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship witch clinical-pathological features. Coll Antropol 2008; 32: 731-6.
22. Vansteenkiste JF, Zielinski M, Dahabreh IJ, Linder A. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer. J Clin Oncol 2008; 26 (15S Suppl.): 7501.
23. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009; 10: 371-4.
24. Schultz ES, Lethe B, Cambiaso CL, et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T Lymphocytes. Cancer Res 2000, 60: 6272-5.
25. Winter H, van den Engel NK, Rusan M, et al. Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis 2011; 3 (2): 105-14.
26. Vansteenkise J, Zieliński M, Linder A, et al. Final results of a multi-center, doube-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II nn-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25: abstract 7554.
27. Brahmer JR. Harnessing the immune system for the treatment of non-small cell lung cancer. J Clin Oncol 2013; 31: 1021-8.
28. Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for Non-small cell lung cancer. Novel Approaches to improve patient outcome. J Thorac Oncol 2011; 6: 1763-73.
29. Roman-Gomez J, Jimenez-Veasco A, Agirre X. Epigenetic regulation of PRAME gene in chronic myelotic leukaemia. Leuk Res 2007; 31: 1521-8.
30. Epping MT, Wang L, Edel MJ. The human tumor antigen PRAMEis a dominant repressor of retinoic acid receptor signalling. Cell 2005; 122: 835-47.
31. Vansteenkiste J, Zielinski M, Dahabreh IJ, et al. Association of gene expression signature and clinical efficacy of MAGE-A3antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26 (15 Suppl.): 397s.
32. Grinstead JS, Koganty RR, Krantz MJ, Longenecker BM, Campbell AP. Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions. Biochemistry 2002; 17: 391-9.
33. Agrawal B, Longenecker BM. MUC1 mucin-mediated regulation of human T cells. Int Immunol 2005; 17: 391-9.
34. Guddo F, Giatromanoaki A, Koukourakis MI, et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998; 51: 667-71.
35. Woenckhaus M1, Merk J, Stoehr R, et al. Prognostic value of FHIT, CTNNB1 and MUC1 expression in non-small cell lung cancer. Hum Patol 2008; 39: 126-36.
36. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161: 589-94.
37. Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. J Thorac Oncol 2007; 2: s332-3.
38. Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small cell lung cancer: review of agents in phase III development. Ann Oncol 2012; 23: 1387-93.
39. Butts C, Anderson H, Maksymiuk A, et al. Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(15 Suppl.): abstract 3055.
40. Butts C, Socinski MA, Mitchell P. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 2013; 31 (suppl): abstract 7500.
41. Kroemer G, Zitvogel L, Galluzzi L. Victories and deceptions in tumor immunology. Oncoimmunology 2013; 2: e23687
42. Ramlau R, Quoix E, Rolski J, et al. A phase II study of TG4010 (MVA-MUC1- IL-2) In association with chemotherapy In patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008; 3: 735-44.
43. Acres B, Quoix E, Ramlau R, et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol 2009; 27 (15 Suppl.): abstract 3027.
44. Ramlau R, Weestel V, Papai Z, et al. Randomized phase IIB trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL-2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26 (15S Suppl.): abstract 8023.
45. Limacher J.M, Quoix E. TG4010: A therapeutic vaccine against MUC1 expressing tumors. Oncoimmunology 2012; 1: 791-2.
46. Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 1999; 125: 61-70.
47. González G, Crombet T, Catalá M, Mirabal V, Hernández JC, González Y, Marinello P, Guillén G, Lage A. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998; 9: 431-435.
48. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for nonsmall cell lung cancer therapy. MEDICC Rev 2010; 12: 17-23.
49. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small cell lung cancer. J Clin Oncol 2008; 26: 1452-1458.
50. Crombet Ramos T, Neninger E, Gonzales J. EGF-based cancer vaccine: Optimizing predictive and surrogate biomarkers. J Clin Oncol 2013; 31 (suppl): abstract 3013.
51. Gardia B, Neninger E, de la Torre A et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008; 14: 840-6.
52. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogenic tumor cell vaccine in non-small cell lung cancer. J Clin Oncol 2006; 24: 4721-30.
53. Fakhrai H, Tong A, Nemunaitis J, et al. Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. J Clin Oncol 2009; 27 (15S).
54. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta 1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999; 86: 1712-9.
55. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. Tissue micro array analysis of ganglioside Nglycolyl GM3 expression and signal transducer andactivator of transcription (STAT-3) activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 2009; 9: 180.
56. Alfonso S, Diaz RM, de la Torre A, et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer. Experience in stage IIIB/IV patients. Cancer Biol Ther 2007; 6: 1847-52.
57. Macias A, Alfonso S, Santiesteban E. Active specific immunotherapy with racotumomab in the treatment of advanced non-small cell lung cancer. Ann Oncol 2012; 23 suppl 9: abstract 1238PD.